- Home
- ACRS vs CHN Comparison
ACRS vs CHN Comparison
Compare ACRS & CHN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- CHN
- Stock Information
- Founded
- ACRS 2012
- CHN 1992
- Country
- ACRS United States
- CHN United States
- Employees
- ACRS N/A
- CHN N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- CHN Investment Managers
- Sector
- ACRS Health Care
- CHN Finance
- Exchange
- ACRS Nasdaq
- CHN Nasdaq
- Market Cap
- ACRS 198.2M
- CHN 174.6M
- IPO Year
- ACRS 2015
- CHN N/A
- Fundamental
- Price
- ACRS $1.89
- CHN N/A
- Analyst Decision
- ACRS Strong Buy
- CHN
- Analyst Count
- ACRS 9
- CHN 0
- Target Price
- ACRS $9.25
- CHN N/A
- AVG Volume (30 Days)
- ACRS 1.1M
- CHN 31.8K
- Earning Date
- ACRS 11-05-2025
- CHN 01-01-0001
- Dividend Yield
- ACRS N/A
- CHN 0.19%
- EPS Growth
- ACRS N/A
- CHN N/A
- EPS
- ACRS N/A
- CHN N/A
- Revenue
- ACRS $16,789,000.00
- CHN N/A
- Revenue This Year
- ACRS N/A
- CHN N/A
- Revenue Next Year
- ACRS $7.02
- CHN N/A
- P/E Ratio
- ACRS N/A
- CHN N/A
- Revenue Growth
- ACRS N/A
- CHN N/A
- 52 Week Low
- ACRS $1.05
- CHN $9.00
- 52 Week High
- ACRS $5.17
- CHN $12.98
- Technical
- Relative Strength Index (RSI)
- ACRS 48.51
- CHN N/A
- Support Level
- ACRS $1.81
- CHN N/A
- Resistance Level
- ACRS $1.94
- CHN N/A
- Average True Range (ATR)
- ACRS 0.09
- CHN 0.00
- MACD
- ACRS -0.01
- CHN 0.00
- Stochastic Oscillator
- ACRS 27.51
- CHN 0.00
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
About CHN China Fund Inc. (The)
CHINA FUND INC is a non-diversified, closed-end management investment company. Its investment objective is a long-term capital appreciation which it seeks to achieve by investing in equity securities with trading in China and outside China. It invests in various industries such as Insurance, Entertainment, Machinery, Electrical Equipment, Beverages, Hotels, Restaurants, and Leisure among others.